Summary

- Microspheres containing radioactive yttrium-90 ($^{90}$Y) are infused into the hepatic artery. These deliver high doses of ionizing radiation to inoperable hepatocellular carcinoma, the most common type of primary liver cancer.
- Limited evidence from several case series indicates that palliative therapy with $^{90}$Y microspheres may reduce tumour size and increase survival time.
- In some patients, $^{90}$Y treatment may result in enough tumour reduction to permit liver resection or transplantation.
- While $^{90}$Y microsphere therapy is generally well tolerated, major complications and several treatment-related deaths have occurred. Improved patient selection criteria and technical changes to microsphere delivery have reduced the risks of complications and death.
- Patient selection and the technical aspects of $^{90}$Y microsphere treatment are complex and require the coordinated expertise of a multidisciplinary team.

Background

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It usually develops in individuals with chronic liver disease, particularly those with viral hepatitis. $^{1}$ HCC is an aggressive disease, especially when chronic liver disease and cirrhosis are present. $^{2}$ It is often at an advanced stage when diagnosed. $^{1,3}$ The median survival time from diagnosis is approximately six to 20 months. $^{2}$

The Technology

Intrahepatic (in the liver) administration of microspheres that contain radioactive yttrium-90 ($^{90}$Y) is an emerging palliative treatment for some patients with inoperable primary liver cancer.

The microspheres are delivered using a catheter that is inserted through an incision in the groin and guided to the artery that supplies blood to the liver. The microspheres can be directed to the entire liver or to subregions, where they lodge in the hepatic arterioles (branches of the artery) and embolize (occlude) the blood vessels feeding the tumour. The microspheres also exert a radiotherapeutic effect by emitting beta radiation that destroys local tumour tissue with little damage to surrounding normal tissue. $^{90}$Y has a half-life of 64.2 hours and an average tissue penetration of 2.5 mm. After they decay to stable zirconium 90, the inert, non-biodegradable microspheres remain in the liver. $^{3}$

The use of $^{90}$Y microspheres in the treatment of liver metastases from colorectal and neuroendocrine cancers is not assessed in this bulletin.

Regulatory Status

Two $^{90}$Y microsphere products are commercially available: TheraSphere$^{®}$ (MDS Nordion, Ottawa) and SIR-Spheres$^{®}$ (Sirtex Medical Limited, Lane Cove, Australia). Only TheraSphere is currently licensed in Canada.
TheraSphere was licensed in February 2005 as a Class III medical device for the treatment of hepatic neoplasia in patients who have appropriately positioned hepatic arterial catheters (Sarah Chandler, Medical Devices Bureau, Health Canada, Ottawa: personal communication, 2007 Jul 25). Prior to this, TheraSphere was licensed in Canada as a drug.4

TheraSphere received a Humanitarian Device Exemption from the US Food and Drug Administration (FDA) in 1999, for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable HCC who can have placement of appropriately positioned hepatic arterial catheters.5 TheraSphere was cleared for marketing in the European Union in 1998.5

SIR-Spheres is not licensed for use in Canada. The US FDA gave SIR-Spheres pre-marketing approval in 2002, to be used with intrahepatic fluorixidine for the treatment of colorectal metastases to the liver.5 The use of SIR-Spheres for the treatment of HCC in the US is an off-label (unapproved) indication. SIR-Spheres received regulatory approval in Australia in 1998 and in the European Union in 2002, for the treatment of patients with advanced inoperable liver cancer (Heather Winslade, Sirtex Medical Ltd., Lane Cove, Australia: personal communication, 2007 May 6).

Patient Group

In 2003, there were 820 new cases of primary liver cancer reported in Canada and 460 deaths due to the disease. Males are affected about three times more often than females.7 Although HCC is relatively rare in North America, its incidence has risen with the increase in hepatitis C and hepatitis B infections.8

Current Practice

There are four established treatments for HCC: resection, transplantation, ablation, and embolization. The treatment options are determined by tumour stage and the degree of liver impairment.3 Surgical resection of the tumour or liver transplantation offer a high rate of complete response and a potential for cure.3 Only about 20% of patients with HCC are surgical candidates because of the presence of extensive disease or poor liver function.3,10 The availability of organs for transplantation is also a limitation.3

Percutaneous ablation with ethanol injection and radiofrequency ablation are treatment options for early stage, unresectable HCC.3 More widespread disease is treated with transarterial embolization (TAE), which deprives the tumour of its blood supply by blocking or embolizing the hepatic artery. When TAE is combined with the injection of chemotherapeutic agents that are usually mixed with lipiodol (a contrast agent), the procedure is called “transarterial chemoembolization” (TACE). TACE has been shown to modestly increase survival in selected patients9,11,12 and has become the standard treatment for unresectable HCC.11

The Radioembolization Brachytherapy Oncology Consortium recently developed clinical guidelines for the use of 90Y microspheres in the treatment of liver cancer. The guidelines, which were supported by unrestricted industry educational grants, describe the ideal candidate for 90Y microsphere therapy as a patient with unresectable primary liver disease, liver-dominant tumour burden, and a life expectancy greater than three months.13

The Evidence

There have been no direct comparisons of the efficacy of the two 90Y microsphere products.13 No randomized controlled trials (RCTs) have compared TheraSphere or SIR-Spheres therapy with other treatment options for HCC. Information from the largest case series is summarized in Table 1. None of these case series reported on post-treatment quality of life.

One cohort study reported modestly improved functional well-being and health-related quality of life scores at three months in 14 patients treated with TheraSphere compared with 14 patients treated with a hepatic artery infusion of cisplatin (p<0.001). At six months, the overall health-related quality of life was no longer significantly different between the two treatment groups nor was there a difference in survival rates.14

Adverse Effects

90Y microsphere therapy seems to be relatively well tolerated. A mild postembolization syndrome, consisting of fatigue, nausea, and abdominal pain, is common for up to three days after treatment.13 Abdominal pain does not usually occur with TheraSphere because of its smaller embolic load.11 Transient fatigue is the most commonly reported adverse effect.11 Other adverse effects include diarrhea, low-grade fever, shaking, chills, lymphopenia, thrombocytopenia, transient decrease in hemoglobin, and abnormal liver function tests.15,17 Radiation-induced liver disease may occur 30 to 90 days after treatment, with the development of fibrosis or cirrhosis, ascites, portal hypertension, varices, and permanently elevated liver function tests.13 This is more likely to occur in patients with more extensive liver disease and tumour burden.

Major complications have occurred because of the inadvertent flow (shunting) of microspheres from the liver into the lung, gastrointestinal tract, or pancreas. This may result in gastrointestinal ulceration, pancreatitis, cholecystitis, radiation pneumonitis, and radiation hepatitis.15,18,19 Several deaths, possibly treatment-related, were reported during the early use of 90Y microsphere therapy.6,20,21 The incidence of non-target radiation is minimized if meticulous angiographic and dosimetry techniques are used.13
A historical comparison was used in place of a control group to compare survival in individuals treated in the past who did not receive 90Y microsphere therapy.

Okuda is a classification system used for staging liver cancer.

For comparison between Okuda stage I and stage II patients.

<table>
<thead>
<tr>
<th>Case Series</th>
<th>Number of Patients (n)</th>
<th>Median Survival</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>TheraSphere</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dancey et al., 2000$^{11}$</td>
<td>22</td>
<td>Okuda* stage I patients (n=9) Okuda stage II patients (n=11)</td>
<td>54 weeks</td>
</tr>
<tr>
<td>Carr, 2004$^{22}$</td>
<td>65</td>
<td>Okuda stage I patients (n=42) Okuda stage II patients (n=23)</td>
<td>Okuda* stage I patients (n=42; 649 days (historical comparison† 244 days) Okuda stage II patients (n=23; 302 days (historical comparison 64 days))</td>
</tr>
<tr>
<td>Geschwind et al., 2004$^{20}$</td>
<td>80</td>
<td>(low risk patients selected from a database of 108 patients) Okuda stage I patients (n=54) Okuda stage II patients (n=26)</td>
<td>Okuda stage I patients (n=54; 628 days Okuda stage II patients (n=26; 384 days (p=0.02))‡</td>
</tr>
<tr>
<td>Salem et al., 2005$^{31}$</td>
<td>43</td>
<td>Okuda stage I patients (n=21) Okuda stage II patients (n=22)</td>
<td>Okuda stage I patients (n=21; 24.4 months Okuda stage II patients (n=22; 12.5 months (p=0.0001))</td>
</tr>
<tr>
<td>Goin et al., 2005$^{9}$</td>
<td>121</td>
<td>Low risk group (n=88) High risk group (n=33)</td>
<td>466 days in low risk group (n=88) versus 108 days in high risk group (n=33) (hazard ratio 6.0; 95% CI 3.6 to 10.1, p=0.0001)</td>
</tr>
<tr>
<td>Kulik et al., 2006$^{24}$</td>
<td>35 (a selected subset of 150 patients who were treated with the specific intent to downstage to liver transplantation, surgical resection, or radiofrequency ablation</td>
<td>800 days Survival at one, two, and three years was reported as 84%, 54%, and 27%, respectively.</td>
<td>A &gt;50% reduction in tumour size was reported in 17 patients. Nineteen patients initially staged as being ineligible for transplant were deemed eligible for transplant following TheraSphere treatment. Eight patients subsequently received liver transplants and one patient underwent tumour resection. One patient had grade 3 bilirubin toxicity.</td>
</tr>
<tr>
<td>SIR-Spheres</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lau et al., 1994$^{25}$</td>
<td>18</td>
<td></td>
<td>30.6 weeks (for all patients who received SIR-Spheres)</td>
</tr>
<tr>
<td>Lau et al., 1998$^{36}$</td>
<td>71</td>
<td></td>
<td>9.4 months (range 1.8 to 46.4 months)</td>
</tr>
<tr>
<td>Sangro et al. 2006$^{27}$</td>
<td>24</td>
<td></td>
<td>7 months</td>
</tr>
</tbody>
</table>

* Okuda is a classification system used for staging liver cancer.
† A historical comparison was used in place of a control group to compare survival in individuals treated in the past who did not receive 90Y microsphere therapy.
‡ For comparison between Okuda stage I and stage II patients.

---

The Canadian Agency for Drugs and Technologies in Health (CADTH) is funded by Canadian federal, provincial, and territorial governments. (www.cadth.ca)
While TheraSphere and SIR-Spheres are both $^{90}$Y-emitting radiotherapeutic devices, they differ in their physical attributes, mechanism of action, and administration.

**TheraSphere**

TheraSphere consists of glass microspheres, with $^{90}$Y as an integral constituent. Each glass sphere has a mean diameter of 25 microns (μm) and contains approximately 2,500 becquerel (Bq), which is a measure of radiation emission. The recommended radiation dose to the liver is between 80 Gy and 150 Gy (the absorbed dose) and is based on the mass of the target liver tissue and the presence and degree of cirrhosis. The dose must be adjusted for vascular shunting to the lung. One million to eight million microspheres are delivered per treatment. This is insufficient to cause significant blockage in the main hepatic artery.

TheraSphere is supplied in 0.6 mL of sterile water, in a vial with an outer acrylic shield. TheraSphere is available in six dose sizes, ranging from 3 GBq to 20 GBq, and is ordered and delivered so that vial contents decay to the required treatment activity for a planned administration date. A pre-assembled single-use TheraSphere Administration Set and needle guide set are provided with each dose. User sites are supplied with a TheraSphere Administration Accessory Kit, which includes re-usable items such as a shielding acrylic box, support stand, handling tools, and radiation dosimeters.

**SIR-Spheres**

SIR-Spheres are resin-based $^{90}$Y microspheres. Each sphere has a diameter of 20 μm to 60 μm and contains approximately 50 Bq. Vials are protected by a lead pot and contain between 40 million to 80 million $^{90}$Y microspheres in 5 mL of sterile water. The vial is calibrated to deliver 3 GBq of $^{90}$Y on the planned treatment date; however, the activity of the vial must be verified with a dose calibrator and may be adjusted and customized in a nuclear pharmacy by diluting with sterile water. An administration set is provided with each dose.

The dosimetry for SIR-Spheres is based on tumour burden, and is adjusted for patients who have shunting of blood to the lungs that could result in radiation pneumonitis. An average treatment delivers 40 million to 60 million spheres, which can cause arterial embolization.

**Administration and Cost**

**Pre-treatment investigation and work-up**

- A pre-treatment angiogram is required to assess the blood supply to the liver and to verify the delivery route.
- A nuclear scan with a radioactive tracer (technetium-99-labelled macroaggregated albumin) is performed before each treatment to measure the percentage of potential shunting (leakage) of $^{90}$Y microsphere from the liver to the lung and gastrointestinal (GI) tract. SIR-Spheres treatment requires dose reduction for lung shunting $>10\%$ and is contraindicated if lung shunting is $>20\%$. TheraSphere is contraindicated if more than 30 Gy of radiation would be delivered to the lung per treatment session. If shunting to the GI tract is present, blood vessels are occluded with coils or gel foam to minimize the potential for radiation gastritis and ulceration caused by microsphere leakage. TheraSphere and SIR-Spheres are contraindicated if GI shunting cannot be corrected.

- A computed tomography (CT) or magnetic resonance imaging (MRI) scan of the liver is essential to calculate the required dose. This is based on the liver volume for TheraSphere and tumour burden for SIR-Spheres. Positron emission tomography (PET) may be used to clarify MRI or CT findings.
- Pre-treatment blood work is performed to evaluate liver function and measure tumour markers.

TheraSphere and SIR-Spheres are contraindicated in patients who have disseminated extra-hepatic malignant disease, severe liver dysfunction, or portal vein occlusion. TheraSphere is also contraindicated in patients with ascites, pulmonary insufficiency, or those who cannot undergo hepatic artery catheterization. SIR-Spheres treatment is contraindicated in patients who have received previous beam radiation therapy to the liver or capecitabine chemotherapy two months before, or at any time after, SIR-Spheres treatment.

**b) Treatment procedure**

If disease is present in both liver lobes, a single liver infusion or sequential unilobar liver treatments are used. The $^{90}$Y microspheres are delivered to the liver using a catheter that is threaded into the femoral artery through a small incision in the groin and guided to the hepatic artery by fluoroscopy (x-ray imaging). Patients are sedated during the outpatient procedure, which is performed in a hospital radiology department. After SIR-Spheres delivery, a single-photon emission computerized tomography (SPECT) scan is performed to confirm placement in the liver. Patients are typically discharged from hospital on the same day, because beta radiation from the $^{90}$Y microspheres does not require medical confinement for radiation safety.

**c) Follow-up**

Patients are followed up with laboratory tests and imaging at 30 days to assess the degree of tumour shrinkage. A second treatment for additional lobes is scheduled if a positive response is achieved. Further follow-up occurs at three-month intervals.


d) Cost

The cost of TheraSphere in the US market is US$13,000. A Canadian price can be obtained by contacting MDS Nordion directly (Tamra Benjamin, MDS Nordion, Ottawa, ON: personal communication, 2007 Jul 19). Each SIR-Spheres treatment costs US$14,000 (Heather Winslade: personal communication, 2007 May 6). These prices do not include costs associated with treatment administration and follow-up.

Concurrent Developments

Hormonal manipulation, gene therapy, immunotherapy, new noncytotoxic drugs, and specific inhibition of angiogenesis and growth factors are new treatment options for HCC that are under investigation.12 Drug-eluting microspheres are also being investigated.30 Phase III trials are underway with sorafenib, an oral multikinase inhibitor with potentially broad-spectrum anti-tumour activity against HCC.31

90Y microsphere therapy is being investigated for the treatment of breast and neuroendocrine tumours that have metastasized to the liver.30 Other potential applications of 90Y microsphere treatment include a combined use with other liver-directed therapies, such as radiofrequency ablation and TACE.30

Rate of Technology Diffusion

Since 2003, MDS Nordion has supplied TheraSphere to treat more than 60 patients with liver cancer in Canada (Tamra Benjamin, MDS Nordion, Ottawa, ON: personal communication, 2007 Jul 19).

90Y resin microspheres (SIR-Spheres) have mainly been used with intrahepatic floxuridine to treat metastatic liver disease, particularly from colorectal cancer. TheraSphere has been used in the treatment of colorectal cancer that has metastasized to the liver.

The incidence and mortality of HCC are expected to increase in Canada over the next several years because of the increasing prevalence of people infected with hepatitis B and hepatitis C. Hepatitis prevention strategies such as hepatitis B vaccination and hepatitis C awareness campaigns are expected to eventually reduce the incidence of HCC.8,32

Implementation Issues

Treatment planning, dosimetry calculation, and the technical aspects of 90Y microsphere administration are complex and require the coordinated expertise of an experienced multidisciplinary team comprising radiation oncologists, nuclear medicine specialists, medical oncologists, hepatologists, and interventional radiologists.11,15 Microsphere manufacturers provide education, on-site training, and support.28,29 Device distribution is limited to institutions that are licensed to handle radioactive materials, including the 90Y isotope.19,29

Limited evidence from several case series indicates that treatment with 90Y microspheres is a palliative option that may reduce tumour size, with a potential for increased survival. A small number of patients may experience sufficient tumour reduction to become eligible for liver resection or transplantation.

Risks versus benefits must be considered for each patient because of the potential for 90Y microsphere-related liver failure and other potentially life-threatening events.

Early data suggest that there are fewer adverse effects and survival is similar with 90Y microsphere treatment compared with transarterial chemoembolization therapy.20 Head-to-head controlled trials are needed to compare 90Y microsphere therapy with existing therapies for hepatocellular carcinoma.

References


---

**Cite as:** Allison C. *Yttrium-90 microspheres (TheraSphere® and SIR-Spheres®) for the treatment of unresectable hepatocellular carcinoma [Issues in emerging health technologies issue 102]*. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.

**************

CADTH takes sole responsibility for the final form and content of this bulletin. The statements and conclusions in this bulletin are those of CADTH, and not those of its advisory committee members or reviewers.

CADTH thanks the external reviewers who kindly provided comments on an earlier draft of this bulletin. David Valenti, MD, McGill University, agreed to be acknowledged as a reviewer of this bulletin.

Conflict of Interest: The centre where Dr. Valenti practises uses TheraSphere®.

Production of this report is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Prince Edward Island, Saskatchewan, and Yukon. The Canadian Agency for Drugs and Technologies in Health takes sole responsibility for the final form and content of this report. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government.

ISSN 1488-6324 (online)  
ISSN 1488-6316 (print)  
PUBLICATIONS MAIL AGREEMENT NO. 40026386  
RETURN UNDELIVERABLE CANADIAN ADDRESSES TO  
CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH  
600-865 CARLING AVENUE  
OTTAWA ON K1S 5S8